Evobrutinib
How it works: Reaching inflammation inside the brain →
In development for MS or related diseases. No approval for these conditions is recorded in the bank.
- Molecule type
- Small molecule
- Mechanism (ChEMBL)
- Tyrosine-protein kinase BTK inhibitor
- Targets
- Tyrosine-protein kinase BTK
Approvals
None recorded.
Safety communications
None recorded.
Trials
Other trials (5)
Completed small trials, dose-finding studies and trials in other diseases.
- Evobrutinib, phase 3
Terminated · Phase 3 · Relapsing and progressive · stopped_other
- Evobrutinib, phase 3
Terminated · Phase 3 · Relapsing and progressive · stopped_other
- Evobrutinib, phase 3
Terminated · Phase 3 · Relapsing and progressive · stopped_other
- Evobrutinib, phase 3
Terminated · Phase 3 · Relapsing and progressive · stopped_other
- Evobrutinib, phase 2
Terminated · Phase 2 · Relapsing and progressive · Stopped: no effect
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error